Dear Editor, I wish to congratulate Jeong and colleagues for their article [1] in which the characteristics and prognosis of post-transplant breast cancer (PTBC) patients receiving immunosuppressants and general breast cancer patients were compared. They reported that subtype and prognosis of breast cancer were comparable with that in the general cohort and immunosuppressants do not adversely affect breast cancer prognosis. In this study, 24 were diagnosed with PTBC. Of the 24 PTBC cohort, 12 received mammalian target of rapamycin (mTOR) inhibitor-tacrolimus as immunosuppressive agent. Results of both the TAMRAD and BOLERO-2 studies showed that mTOR inhibition in combination with endocrine therapy improved progression-free survival for hormone receptor-positive metastatic breast cancer patients [2] . For this reason, it would be interesting to compare the outcome of hormone receptor-positive PTBC patients who received endocrine treatment and tacrolimus with hormone receptor-positive patients in general cohort.
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